Clinical outcomes of 62 patients with prostate carcinoma treated with three-dimensional conformal radiotherapy or intensive modulated radiotherapy
10.3760/cma.j.issn.1004-4221.2010.03.016
- VernacularTitle:62例前列腺癌三维适形或调强放疗的临床研究
- Author:
Qiuzi ZHONG
;
Gaofeng LI
;
Yonggang XU
;
Xia XIU
;
Qinhong WU
;
Suhua XIAO
;
Mingyuan LIU
- Publication Type:Journal Article
- Keywords:
Prostate neoplasm/radiotherapy;
Radiotherapy,three-dimensional conformal;
Prognosis;
Prostate specific antigen
- From:
Chinese Journal of Radiation Oncology
2010;19(3):231-235
- CountryChina
- Language:Chinese
-
Abstract:
Objective To evaluate the prognosis and side-effects of three-dimensional conformal radiotherapy (3 DCRT) and intensity modulated radiotherapy (IMRT) for prostate carcinoma. Methods From 2001 to 2009, 62 patients with prostate carcinoma treated with radiotherapy were included in the retrospective analysis. Among them, 60 patients received IMRT while the other two received 3DCRT. There were 56 patients receiving androgen deprivation therapy before radiotherapy. The median dose was 78 Gy to 95% planning target volume (PTV) of the prostate and seminal vesicles, and the median dose to 95% PTV of the pelvic lymph nodes was 48 Gy. Results The median follow-up was 15.4 months. The 3-and 5-year overall survival (OS) rates were 92% and 83%, with the corresponding biochemical disease-free survival rates of 87% and 69%, and the distant metastasis-free survival (DMFS) rate of 77% and 55%, respectively. Patients with a PSA nadir ≤ 2 ng/ml had a 3-year OS of 94% and DMFS of 88%, compared with 56% and 11% (χ~2 = 16. 39, P < 0.01 for OS ; χ~2 = 28. 87, P < 0. 01 for DMFS) for those with a PSA nadir > 2 ng/ml. The incidence of grade 1 and 2 urinary toxicity was 32% and 0% for acute damage, 10% and 0% for late damage, respectively. The incidence of grade 1 and 2 intestinal toxicity was 19% and 3%. for acute damage, 5% and 3% for late damage, respectively. Conclusions Radiation therapy for patients with prostate carcinoma shows satisfactory outcomes with a good toleration. Monitor of PSA after radiotherapy has benefit for prognosis evaluation.
